HD Pharm

HD Pharm is a South Korean pharmaceutical company specializing in the development of Incrementally Modified Drugs (IMDs) and Fixed-Dose Combinations (FDCs). Founded in 2014, the company focuses on improving patient compliance and therapeutic efficacy by combining existing active pharmaceutical ingredients into optimized formulations. Their R&D pipeline primarily targets chronic conditions such as hypertension, diabetes, and dyslipidemia, with several triple-combination therapies in late-stage clinical trials. In addition to its proprietary drug development, HD Pharm provides Contract Development and Manufacturing Organization (CDMO) services, leveraging its KGMP-certified facilities. The company is a significant player in the domestic Korean market for value-added generics and improved new drugs.